This suggests that one of the major debilitating symptoms of Alzheimer’s disease—the loss of ability to form new long-term memories—may be restored at a fundamental level by therapeutics targeting S2R. The gene discussed is TMEM97; the disease is early-onset autosomal dominant Alzheimer disease.